Vulvar Cancer – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Vulvar Cancer – Pipeline Review, H2 2017’, provides an overview of the Vulvar Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vulvar Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Vulvar Cancer

The report reviews pipeline therapeutics for Vulvar Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Vulvar Cancer therapeutics and enlists all their major and minor projects

The report assesses Vulvar Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Vulvar Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Vulvar Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vulvar Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Cutanea Life Sciences Inc

ISA Pharmaceuticals BV

MedImmune LLC

Ono Pharmaceutical Co Ltd

Oryx GmbH & Co KG

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Vulvar Cancer - Overview 5

Vulvar Cancer - Therapeutics Development 6

Pipeline Overview 6

Pipeline by Companies 7

Products under Development by Companies 8

Vulvar Cancer - Therapeutics Assessment 9

Assessment by Target 9

Assessment by Mechanism of Action 11

Assessment by Route of Administration 13

Assessment by Molecule Type 15

Vulvar Cancer - Companies Involved in Therapeutics Development 17

Cutanea Life Sciences Inc 17

ISA Pharmaceuticals BV 17

MedImmune LLC 17

Ono Pharmaceutical Co Ltd 18

Oryx GmbH & Co KG 18

Vulvar Cancer - Drug Profiles 19

durvalumab + tremelimumab - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

ISA-101 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

nivolumab - Drug Profile 31

R&D Progress 32

omiganan pentahydrochloride - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Vicoryx - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Vulvar Cancer - Dormant Projects 88

Vulvar Cancer - Product Development Milestones 89

Featured News & Press Releases 89

Oct 05, 2011: FDA Grants ISA Pharmaceuticals Orphan Drug Designation For Treatment Of Vulvar Intraepithelial Neoplasia With ISA-HPV-SLP 89

Mar 07, 2011: ISA Pharma Receives €2.7m From Dutch Government To Further Clinical Development Of HPV-SLP Vaccine 89

Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 89

Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 90

Appendix 91

Methodology 91

Coverage 91

Secondary Research 91

Primary Research 91

Expert Panel Validation 91

Contact Us 91

Disclaimer 92

List of Tables

List of Tables

Number of Products under Development for Vulvar Cancer, H2 2017 6

Number of Products under Development by Companies, H2 2017 7

Products under Development by Companies, H2 2017 8

Number of Products by Stage and Target, H2 2017 10

Number of Products by Stage and Mechanism of Action, H2 2017 12

Number of Products by Stage and Route of Administration, H2 2017 14

Number of Products by Stage and Molecule Type, H2 2017 16

Vulvar Cancer – Pipeline by Cutanea Life Sciences Inc, H2 2017 17

Vulvar Cancer – Pipeline by ISA Pharmaceuticals BV, H2 2017 17

Vulvar Cancer – Pipeline by MedImmune LLC, H2 2017 18

Vulvar Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 18

Vulvar Cancer – Pipeline by Oryx GmbH & Co KG, H2 2017 18

Vulvar Cancer – Dormant Projects, H2 2017 88

List of Figures

List of Figures

Number of Products under Development for Vulvar Cancer, H2 2017 6

Number of Products under Development by Companies, H2 2017 7

Number of Products by Targets, H2 2017 9

Number of Products by Stage and Targets, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 11

Number of Products by Routes of Administration, H2 2017 13

Number of Products by Stage and Routes of Administration, H2 2017 13

Number of Products by Molecule Types, H2 2017 15

Number of Products by Stage and Molecule Types, H2 2017 15

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports